October 24, 2026
CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026
CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit...
Read More
October 6, 2026
CatalYm to Present Updated GDFATHER-NEO Clinical Data and Highlight Ongoing Phase 2b Visugromab Trials at ESMO 2026
CatalYm to Present Updated GDFATHER-NEO Clinical Data and Highlight Ongoing Phase 2b...
Read More
June 9, 2026
CatalYm Appoints Peter Garcia as Chief Financial Officer
CatalYm Appoints Peter Garcia as Chief Financial Officer Munich, Germany and...
Read More
April 28, 2026
CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors
CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors...
Read More
April 23, 2026
CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First Patient Dosed
CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First...
Read More